Baxter raises annual profit forecast on strong demand for medical devices
Corrects to add story keyword used by media customers
May 2 (Reuters) -Medical device maker Baxter International BAX.N raised its annual profit forecast and beat quarterly estimates on Thursday, banking on strong demand for its infusion pumps and dialysis products.
Investor expectations around the performance of medical device makers have been heightened since last November due to higher demand for procedures, especially among older adults, that were delayed during the COVID-19 pandemic.
Larger peers Stryker SYK.N and Boston Scientific BSX.N also beat profit estimates during their quarterly results, as industry bellwether Johnson & Johnson JNJ.N expects medtech-related procedures to remain elevated in 2024.
Baxter said the separation of its kidney care segment, which was proposed in January last year, is expected to take place in the second half of 2024.
The company expects full-year adjusted profit between $2.88 and $2.98 per share, compared with its previous expectation between $2.85 and $2.95 per share. Analysts estimated a profit of $2.90 per share, according to LSEG data.
The first-quarter revenue rose 2% to $3.59 billion from the previous year, beating estimates of $3.55 billion.
The medical products and therapies segment, which makes IV solutions and infusion pumps, recorded quarterly sales of $1.23 billion, up 6%, compared to analysts' average estimates of $1.16 billion.
The kidney care segment, through which it sells dialysis products, garnered quarterly sales of $1.1 billion, slightly above analysts' estimates of $1.09 billion.
On an adjusted basis, the company earned 65 cents per share, compared with estimates of 61 cents per share.
Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
